Share Prices & Company Research

Stockbroking

Circassia Pharmaceuticals

Current Price 95.00p Bid 94.50p Ask 95.00p Change 0.00%
Last Updated: 24/02/2018 15:45. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Circassia Pharmaceuticals plc is a world-class specialty pharmaceutical business focused on respiratory disease. In addition to its market-leading NIOX products, the Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza, and has the US commercial rights to late-stage COPD product Duaklir. Circassia's development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products.

Financial Highlights Year Ended 31/12/2016

Turnover
£23.10m
Operating Profit
£-151.50m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-1.98

Key Personnel

Steven Charles Andrew Harris
Chief Executive Officer
Julien Fabrice Cotta
Chief Financial Officer
Dr Roderick Peter Hafner
Executive Director
Dr Francesco Granata
Non-Executive Chairman
Marvin S Samson
Non-Executive Director
Dr Timothy Henry Corn
Non-Executive Director
Russell Cummings
Non-Executive Director
Dr Jean-Jacques Garaud
Non-Executive Director
Charles Stuart Webb Swingland
Non-Executive Director
Lota Sue Zoth
Non-Executive Director

Stock Details

EPIC
CIR
ISIN
GB00BJVD3B28
Shares in Issue
333,466,262
Market cap
£316.79m

Analyst Views (2)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
50.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
95.00p
Bid Price
94.50p
Ask Price
95.00p
Volume
16146
Change Today
0.00p
% Change Today
0.00%
Open
94.05p
Previous Close
95.00p
Intraday High
95.00p
Intraday Low
92.09p
52 Week High
114.00p
52 Week Low
76.75p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Circassia Pharmaceuticals Intra-day Chart

Circassia Pharmaceuticals News

News in this section is provided by MoneyAM

Circassia Pharmaceuticals appoints three new non-executive directors 13 Feb 2018 | 14:03 Circassia receives contract from Vizient for asthma management products 08 Feb 2018 | 08:41 FTSE resilient despite spike in sterling 04 Dec 2017 | 16:49 Circassia's Tudorza meets primary endpoints in study 04 Dec 2017 | 07:17 Circassia welcomes new NICE asthma guidelines 29 Nov 2017 | 07:53 Broker Forecast - JP Morgan Cazenove issues a broker note on Circassia Pharmaceuticals Plc 28 Sep 2017 | 10:30 Circassia launches nasal application in Europe 12 Sep 2017 | 08:01 FLASH: Circassia launches nasal application in Europe 12 Sep 2017 | 07:07 Euro strong on European growth upgrade 07 Sep 2017 | 16:37 Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals Plc 07 Sep 2017 | 10:10 Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc 26 Apr 2017 | 14:10 Circassia losses widen 25 Apr 2017 | 09:48 FLASH: Circassia losses rise 25 Apr 2017 | 07:04 FTSE suffers worst day in three months on surprise election news 18 Apr 2017 | 16:38 FTSE dives on election shock 18 Apr 2017 | 11:55 Miners slump on sharp drop in metals prices 18 Apr 2017 | 09:10 Circassia disappointed by house mite dust allergy results 18 Apr 2017 | 07:23 FLASH: Circassia disappointed by house mite dust allergy results 18 Apr 2017 | 07:05 Circassia schedules FY results 12 Apr 2017 | 09:48 Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals Plc 04 Apr 2017 | 15:30 Broker views: G4S and Circassia 20 Mar 2017 | 15:03 Broker Forecast - Stifel issues a broker note on Circassia Pharmaceuticals Plc 20 Mar 2017 | 11:30 FTSE struggles to reach new highs 17 Mar 2017 | 16:56 Banks bolster FTSE 100 17 Mar 2017 | 11:58 FTSE drifts sideways Friday rates-led volatility 17 Mar 2017 | 08:51 Circassia collaboration with AstraZeneca 17 Mar 2017 | 07:30 FLASH: Circassia collaboration with AstraZeneca 17 Mar 2017 | 07:06 Broker Forecast - Peel Hunt issues a broker note on Circassia Pharmaceuticals Plc 24 Feb 2017 | 08:20

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Tangible Assets
1.4
1.3
Intangible Assets & Goodwill
176.8
246.8
Investments & Other Non-Current Assets
17.5
17.4
Total Non-Current Assets
195.7
265.5
Inventory
4.6
3.0
Trade & Receivables
7.7
5.1
Cash & Receivables
97.4
166.0
Other Current Assets & Assets Held for Resale
28.7
49.6
Total Assets
334.1
489.2

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Short Term Liabilities
21.5
48.3
Long Term Liabilities
31.9
31.2
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
53.4
79.5

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Net Assets
280.7
409.7

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Share Capital
0.2
0.2
Minority Interests
0.0
1.2
Retained Earnings
-295.8
-158.5
Share Premium Account
563.8
564.0
Other Equity
12.5
2.8
Total Equity
280.7
409.7

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Cashflow from Operating Activities
-56.7
-55.8
Cashflow Before Financing
-69.1
-122.9
Increase / Decrease in Cash
-72.7
135.7

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Turnover
23.1
10.8
Cost of Sales
8.0
4.3
Gross Profit
15.1
6.5
Operating Profit
-151.5
-66.4
Pre-Tax Profit
-144.9
-62.8
Profit / Loss for the Year
-137.4
-50.0
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.